Introduction: Atypical hemolytic uremic syndrome (aHUS) is a rare, complement-mediated disorder characterized by microangiopathic hemolytic anemia, thrombocytopenia, and acute kidney injury. Eculizumab, a monoclonal antibody that inhibits complement component C5, is a cornerstone therapy for aHUS but increases the risk of infections, particularly from encapsulated organisms. Surgical procedures can also raise infection risks or exacerbate thrombotic microangiopathy. However, data on the perioperative management of patients with aHUS, particularly those receiving eculizumab, remain limited. Case Presentation: A 73-year-old male with a history of prostate cancer presented with acute kidney injury, thrombocytopenia, and hemolysis, leading to a diagnosis of aHUS. He was treated with eculizumab, which improved kidney function and eliminated the need for dialysis. Four months later, he developed abdominal pain and was found to have gallstones. The patient subsequently underwent a laparoscopic cholecystectomy while continuing maintenance eculizumab therapy. The procedure was performed without any complications, and the patient was discharged in stable condition. Conclusion: This case report details the successful perioperative management of a patient with aHUS on maintenance eculizumab undergoing cholecystectomy, highlighting the importance of careful management, including continued complement inhibition and infection prevention strategies. Our report emphasizes the need for individualized perioperative care to minimize risks in aHUS patients requiring surgery.

1.
Laurence
J
,
Haller
H
,
Mannucci
PM
,
Nangaku
M
,
Praga
M
,
Rodriguez de Cordoba
S
.
Atypical hemolytic uremic syndrome (aHUS): essential aspects of an accurate diagnosis
.
Clin Adv Hematol Oncol
.
2016
;
14 Suppl
(
11
):
2
15
.
2.
Legendre
CM
,
Licht
C
,
Muus
P
,
Greenbaum
LA
,
Babu
S
,
Bedrosian
C
, et al
.
Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome
.
N Engl J Med
.
2013
;
368
(
23
):
2169
81
.
3.
McNamara
LA
,
Topaz
N
,
Wang
X
,
Hariri
S
,
Fox
L
,
MacNeil
JR
.
High risk for invasive meningococcal disease among patients receiving eculizumab (soliris) despite receipt of meningococcal vaccine
.
MMWR Morb Mortal Wkly Rep
.
2017
;
66
(
27
):
734
7
.
4.
Gülhan
B
,
Özaltın
F
,
Fidan
K
,
Özçakar
ZB
,
Söylemezoğlu
O
.
Management of pediatric hemolytic uremic syndrome
.
Turk J Pediatr
.
2024
;
66
(
1
):
1
16
.
5.
Kathirvel
S
,
Prakash
A
,
Lokesh
BN
,
Sujatha
P
.
The anesthetic management of a patient with paroxysmal nocturnal hemoglobinuria
.
Anesth Analg
.
2000
;
91
(
4
):
1029
31
.
6.
Musselman
K
,
Laurence
J
,
Magro
C
,
Rahbari
P
,
Di Vitantonio
T
,
Havryliuk
Y
.
Atypical hemolytic uremic syndrome after myomectomy: a case report
.
Case Rep Womens Health
.
2022
;
35
:
e00424
.
7.
Langereis
JD
,
van den Broek
B
,
Franssen
S
,
Joosten
I
,
Blijlevens
NMA
,
de Jonge
MI
, et al
.
Eculizumab impairs Neisseria meningitidis serogroup B killing in whole blood despite 4CMenB vaccination of PNH patients
.
Blood Adv
.
2020
;
4
(
15
):
3615
20
.
8.
Schweitzer
L
,
Miko
BA
,
Pereira
MR
.
Infectious disease prophylaxis during and after immunosuppressive therapy
.
Kidney Int Rep
.
2024
;
9
(
8
):
2337
52
.
9.
Socié
G
,
Caby-Tosi
MP
,
Marantz
JL
,
Cole
A
,
Bedrosian
CL
,
Gasteyger
C
, et al
.
Eculizumab in paroxysmal nocturnal haemoglobinuria and atypical haemolytic uraemic syndrome: 10-year pharmacovigilance analysis
.
Br J Haematol
.
2019
;
185
(
2
):
297
310
.
10.
Wijnsma
KL
,
Ter Heine
R
,
Moes
DJAR
,
Langemeijer
S
,
Schols
SEM
,
Volokhina
EB
, et al
.
Pharmacology, pharmacokinetics and pharmacodynamics of eculizumab, and possibilities for an individualized approach to eculizumab
.
Clin Pharmacokinet
.
2019
;
58
(
7
):
859
74
.
11.
Peffault de Latour
R
,
Fremeaux-Bacchi
V
,
Porcher
R
,
Xhaard
A
,
Rosain
J
,
Castaneda
DC
, et al
.
Assessing complement blockade in patients with paroxysmal nocturnal hemoglobinuria receiving eculizumab
.
Blood
.
2015
;
125
(
5
):
775
83
.
12.
Moriyama
M
,
Nagata
T
,
Yoshioka
I
,
Hashimoto
I
,
Matsui
K
,
Okumura
T
, et al
.
A patient with paroxysmal nocturnal hemoglobinuria being treated with eculizumab who underwent laparoscopic cholecystectomy: report of a case
.
Surg Case Rep
.
2015
;
1
(
1
):
57
.
13.
Kusadokoro
S
,
Kimura
N
,
Hori
D
,
Yamaguchi
A
.
Eculizumab therapy in paroxysmal nocturnal haemoglobinuria patient undergoing aortic valve surgery
.
Interact Cardiovasc Thorac Surg
.
2019
;
28
(
6
):
994
5
.
14.
Li
D
,
Wang
L
,
Horiuchi
I
,
Kimura
SI
,
Chikazawa
K
,
Kimura
A
, et al
.
Preoperative administration of eculizumab to prevent surgery-triggered hemolysis during cesarean section with paroxysmal nocturnal hemoglobinuria
.
Clin Case Rep
.
2018
;
6
(
9
):
1807
9
.
15.
van Bijnen
ST
,
Vermeer
H
,
Mourisse
JM
,
de Witte
T
,
van Swieten
HA
,
Muus
P
.
Cardiopulmonary bypass in a patient with classic paroxysmal nocturnal hemoglobinuria during treatment with eculizumab
.
Eur J Haematol
.
2011
;
87
(
4
):
376
8
.
16.
De-la-Iglesia
S
,
Luzardo
H
,
Lemes
A
,
Torres
M
,
Gómez-Casares
MT
,
Cruz
N
, et al
.
Positive impact of eculizumab therapy on surgery for budd-chiari syndrome in a patient with paroxysmal nocturnal hemoglobinuria and a long-term history of thrombosis
.
Hematol Rep
.
2016
;
8
(
3
):
6562
.
17.
Risitano
AM
,
Marando
L
,
Seneca
E
,
Rotoli
B
.
Hemoglobin normalization after splenectomy in a paroxysmal nocturnal hemoglobinuria patient treated by eculizumab
.
Blood
.
2008
;
112
(
2
):
449
51
.
18.
Ando
K
,
Gotoh
A
,
Yoshizawa
S
,
Gotoh
M
,
Iwabuchi
T
,
Ito
Y
, et al
.
Successful cholecystectomy in a patient with aplastic anemia-paroxysmal nocturnal hemoglobinuria during eculizumab treatment
.
Ann Hematol
.
2012
;
91
(
12
):
1987
8
.
19.
Kawano
H
,
Minagawa
K
,
Wakahashi
K
,
Kawano
Y
,
Sada
A
,
Matsui
T
, et al
.
Successful management of obstructive jaundice due to gallstones with eculizumab in a patient with paroxysmal nocturnal hemoglobinuria
.
Intern Med
.
2012
;
51
(
18
):
2613
6
.
20.
Tsutsui
M
,
Gotoh
A
,
Yasuda
H
,
Ono
E
,
Tanaka
M
,
Komatsu
N
.
[Successful management of orthopedic operations requiring general anesthesia in a PNH patient after introduction of eculizumab]
.
Rinsho Ketsueki
.
2015
;
56
(
4
):
423
7
.
21.
Singer
AL
,
Locke
JE
,
Stewart
ZA
,
Lonze
BE
,
Hamilton
JP
,
Scudiere
JR
, et al
.
Successful liver transplantation for Budd-Chiari syndrome in a patient with paroxysmal nocturnal hemoglobinuria treated with the anti-complement antibody eculizumab
.
Liver Transpl
.
2009
;
15
(
5
):
540
3
.
You do not currently have access to this content.